1. Home
  2. OCUP vs BWEN Comparison

OCUP vs BWEN Comparison

Compare OCUP & BWEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OCUP
  • BWEN
  • Stock Information
  • Founded
  • OCUP 2018
  • BWEN N/A
  • Country
  • OCUP United States
  • BWEN United States
  • Employees
  • OCUP N/A
  • BWEN N/A
  • Industry
  • OCUP Biotechnology: Pharmaceutical Preparations
  • BWEN Industrial Machinery/Components
  • Sector
  • OCUP Health Care
  • BWEN Industrials
  • Exchange
  • OCUP Nasdaq
  • BWEN Nasdaq
  • Market Cap
  • OCUP 53.1M
  • BWEN 46.4M
  • IPO Year
  • OCUP N/A
  • BWEN N/A
  • Fundamental
  • Price
  • OCUP $1.22
  • BWEN $2.19
  • Analyst Decision
  • OCUP Strong Buy
  • BWEN Strong Buy
  • Analyst Count
  • OCUP 3
  • BWEN 3
  • Target Price
  • OCUP $18.67
  • BWEN $5.17
  • AVG Volume (30 Days)
  • OCUP 90.4K
  • BWEN 100.5K
  • Earning Date
  • OCUP 11-11-2024
  • BWEN 11-06-2024
  • Dividend Yield
  • OCUP N/A
  • BWEN N/A
  • EPS Growth
  • OCUP N/A
  • BWEN N/A
  • EPS
  • OCUP N/A
  • BWEN 0.35
  • Revenue
  • OCUP $16,449,000.00
  • BWEN $177,829,000.00
  • Revenue This Year
  • OCUP N/A
  • BWEN N/A
  • Revenue Next Year
  • OCUP $258.69
  • BWEN $24.98
  • P/E Ratio
  • OCUP N/A
  • BWEN $6.44
  • Revenue Growth
  • OCUP N/A
  • BWEN N/A
  • 52 Week Low
  • OCUP $1.15
  • BWEN $2.01
  • 52 Week High
  • OCUP $3.40
  • BWEN $4.65
  • Technical
  • Relative Strength Index (RSI)
  • OCUP 44.79
  • BWEN 51.07
  • Support Level
  • OCUP $1.24
  • BWEN $2.11
  • Resistance Level
  • OCUP $1.34
  • BWEN $2.35
  • Average True Range (ATR)
  • OCUP 0.08
  • BWEN 0.10
  • MACD
  • OCUP 0.00
  • BWEN 0.01
  • Stochastic Oscillator
  • OCUP 12.00
  • BWEN 57.14

About OCUP Ocuphire Pharma Inc.

Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.

About BWEN Broadwind Inc.

Broadwind Inc is a precision manufacturer of structures, equipment and components for clean technology and other specialized applications. The company provide technologically high value products to customers with complex systems and stringent quality standards that operate in energy, mining and infrastructure sectors, in the United States of America. It capabilities include heavy fabrications, welding, metal rolling, coatings, gear cutting and shaping, gearbox manufacturing and repair, heat treat, assembly, engineering and packaging solutions. It operates through three operating segments namely Heavy Fabrications, Gearing and Industrial Solutions.

Share on Social Networks: